Phosphorus Binder Selection for ESRD Patients

General Considerations

• The American Journal of Kidney Diseases recommends that the choice of phosphate binder should be determined by patient preference, compliance, comorbid illnesses, side effects, cost, and ability to control serum phosphorus levels 1, 2
• The National Kidney Foundation suggests that all currently available phosphate binders are efficacious in controlling serum phosphorus levels 3
• The Annals of Internal Medicine guidelines state that phosphate-lowering treatment decisions should be individualized based on progressively or persistently elevated serum phosphate 4

Alternative Phosphate Binders

• The American Journal of Kidney Diseases recommends Sevelamer as a non-calcium, non-aluminum phosphate binder with proven efficacy and safety 5, 6
• Sevelamer attenuates the progression of arterial calcifications compared with calcium-based phosphate binders, as suggested by the American Journal of Kidney Diseases 6, 7
• The Renagel In New Dialysis Patients trial, published in the American Journal of Kidney Diseases, suggested a significant mortality reduction in incident dialysis patients receiving sevelamer 6
• Sevelamer has been shown to decrease LDL cholesterol levels by 34%, providing additional cardiovascular benefit, according to the American Journal of Kidney Diseases 6

Calcium-Based Binders

• The American Journal of Kidney Diseases states that calcium-based binders (calcium carbonate, calcium acetate) are effective but may cause hypercalcemia 3
• Gastrointestinal side effects were reported to be lowest with calcium carbonate compared to other binders, as noted in the American Journal of Kidney Diseases 3
• The Annals of Internal Medicine guidelines suggest restricting the dose of calcium-based phosphate binders in CKD patients 4
• The American Journal of Kidney Diseases recommends avoiding calcium-based binders in patients with hypercalcemia or severe vascular calcification 2

Management Algorithm

• The American Journal of Kidney Diseases suggests Sevelamer hydrochloride or sevelamer carbonate as a first-line option for phosphorus binding in ESRD patients with GI concerns 5, 6, 7
• The American Journal of Kidney Diseases recommends calcium-based binders as second-line options if no hypercalcemia is present 3
• The American Journal of Kidney Diseases suggests limiting aluminum-based binders to short-term use (≤4 weeks) due to risk of aluminum toxicity 1, 2, 3

Important Clinical Considerations

• The American Journal of Kidney Diseases notes that phosphate binder therapy introduces a significant pill burden that can compromise long-term adherence 8
• The American Journal of Kidney Diseases recommends taking binders 10-15 minutes before or during meals for optimal efficacy 3
• Regular monitoring of serum phosphorus, calcium, and PTH levels is essential, as stated in the American Journal of Kidney Diseases 1
• The American Journal of Kidney Diseases suggests considering intensified dialysis protocols as an alternative approach in patients where phosphate control is difficult 8
• Patient education about the importance of phosphate control and proper medication administration is crucial for treatment success, according to the American Journal of Kidney Diseases 8